Literature DB >> 8885003

Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis?

J Mañá1, A Salazar, R Pujol, F Manresa.   

Abstract

The prognosis of sarcoidosis is difficult to establish. It depends mainly on the persistence of activity over time and the degree of functional impairment of the involved organs. The aim of this study was to analyze whether the pulmonary function tests and the more commonly used markers of activity, such as serum angiotensin-converting enzyme (SACE) and gallium-67 scan, are helpful to evaluate the prognosis of sarcoidosis, besides the clinical data. Over a 14-year period (1974-1987), 209 patients were diagnosed as having sarcoidosis at the Bellvitge Hospital, a 1,000-bed teaching hospital in Barcelona, Spain. Clinical, radiological, pulmonary function tests, and activity markers (SACE and gallium-67 scan) data at diagnosis were collected and classified as variables, and a definition of disease activity was established. One hundred sixteen patients were on follow-up, had all the variables available and were included in the statistical analysis. A Cox proportional-hazard regression model identified the following variables as independently influencing the persistence of activity over time: absence of erythema nodosum [risk ratio (RR) = 2.78; 95% confidence interval (CI): 1.48-5.18], age > or = 40 years (RR = 1.67; 95% CI: 1.008-1.04), SACE level > or = mean + 2 SD U/ml (RR = 1.45; CI: 0.99-1.07), hyperglobulinemia (RR = 2.47; CI: 0.98-6.24), forced vital capacity < 80% predicted (RR = 2.17; CI: 0.97-4.85), and male sex (RR = 1.8; CI: 0.95-3.45). We conclude that the pulmonary function tests and the SACE level but not the gallium scan are helpful to identify the factors predicting persistence of activity in sarcoidosis. Therefore, we recommend to add these tests to the initial clinical evaluation of patients with sarcoidosis in order to establish the prognosis and improve the therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885003     DOI: 10.1159/000196564

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

1.  Sarcoidosis as a risk factor for venous thromboembolism.

Authors:  Anna Goljan Geremek; Witold Tomkowski; Marcin Geremek; Elżbieta Puścińska; Grzegorz Małek; Adam Nowiński; Michal Bednarek; Paweł Śliwiński
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  Catch the rainbow: Prognostic factor of sarcoidosis.

Authors:  Senol Kobak
Journal:  Lung India       Date:  2020 Sep-Oct

3.  Prognostic features of sarcoidosis course in a Brazilian cohort.

Authors:  Marina Dornfeld Cunha Castro; Carlos Alberto de Castro Pereira; Maria Raquel Soares
Journal:  J Bras Pneumol       Date:  2022-02-02       Impact factor: 2.624

4.  Clinical phenotyping in sarcoidosis using cluster analysis.

Authors:  Nancy W Lin; Jaron Arbet; Margaret M Mroz; Shu-Yi Liao; Clara I Restrepo; Annyce S Mayer; Li Li; Briana Q Barkes; Sarah Schrock; Nabeel Hamzeh; Tasha E Fingerlin; Nichole E Carlson; Lisa A Maier
Journal:  Respir Res       Date:  2022-04-09

5.  Clinical characteristics and computed tomography findings in Arab patients diagnosed with pulmonary sarcoidosis.

Authors:  Esam H Alhamad; Mohammed O Alanezi; Majdy M Idrees; Mohammad K Chaudhry; Ali M AlShahrani; Arthur Isnani; Shaffi Shaikh
Journal:  Ann Saudi Med       Date:  2009 Nov-Dec       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.